Tumor Mutational Burden and Response Rate to PD-1 Inhibition

By M. Yarchoan, Alexander C. Hopkins, E. Jaffee. New England Journal of Medicine, 2017

2,701 citations recorded by the source corpus.

In a survey of the spectrum of mutational burdens in 27 types of cancers, there was a correlation between an increased mutational burden and the response to checkpoint inhibition of PD-1 and PD-L1.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/82cd55720cd9f4ada9fd09746798f364c2bad999

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Timothy A. Chan
2. Sergio A. Quezada

Citations in the corpus

• Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic (2018, background): “This may be the reason the subset of Merkel-cell carcinoma that is associated with the Merkel-cell polyomavirus has a moderate TMB [93] but amongst the highest response rates of any tumor type with anti-PD1 therapy [94].”
• Cold Tumors: A Therapeutic Challenge for Immunotherapy (2019, background): “LACK OF TUMOR ANTIGENS Tumor antigens can be divided into three main classes: tumor specific antigens (TSA), cancergermline antigens (CGA), and tumor associated antigens (TAA) (3).”
• Molecular profiling for precision cancer therapies (2020, background): “The second cohort in microsatellite stable colorectal cancer with TMB between 11 and 22 mutations per megabase showed limited clinical benefit, leading to the closure of the arm [39, 167, 172].”